Correlation between clinicopathological features and HRD status in 189 triple-negative breast cancers
| Characteristics | No. (%) | |||
|---|---|---|---|---|
| Total (n = 189) | HRD+ (n = 93) | HRD− (n = 96) | P value | |
| Age, mean (standard deviation), years | 48.3 (9.5) | 46.6 (9.0) | 50.0 (9.7) | 0.01 |
| Menopausal status | 0.07 | |||
| Premenopausal | 102 (54.0) | 57 (61.3) | 45 (46.9) | |
| Postmenopausal | 87 (46.0) | 36 (38.7) | 51 (53.1) | |
| Ki67 proliferation index (%) | ||||
| Median (range) | 60 (5.0, 95.0) | 65 (10.0, 95.0) | 40 (5.0, 95.0) | < 0.001 |
| N/A | 5 | 3 | 2 | |
| Tumor stage | 0.13 | |||
| cT1 | 91 (48.4) | 38 (41.3) | 53 (55.2) | |
| cT2 | 92 (48.9) | 52 (56.5) | 40 (41.7) | |
| cT3 | 5 (2.7) | 2 (2.2) | 3 (3.1) | |
| N/A | 1 | 1 | ||
| Pathological status | 0.15 | |||
| Ductal | 182 (96.3) | 87 (93.5) | 95 (99.0) | |
| Medullary | 4 (2.1) | 3 (3.2) | 1 (1.0) | |
| Others | 3 (1.6) | 3 (3.2) | 0 (0.0) | |
| Histological grade | 0.09 | |||
| II | 52 (29.2) | 20 (22.7) | 32 (35.6) | |
| III | 126 (70.8) | 68 (77.3) | 58 (64.4) | |
| N/A | 11 | 5 | 6 | |
| Clinical stage | 0.15 | |||
| I | 50 (26.5) | 22 (23.7) | 28 (29.2) | |
| II | 91 (48.1) | 52 (55.9) | 39 (40.6) | |
| III | 8 (4.23) | 2 (2.20) | 6 (6.3) | |
| IV | 40 (21.2) | 17 (18.7) | 23 (24.0) | |
| PD-L1 IPS expression | 0.36 | |||
| <1% | 116 (77.9) | 62 (81.6) | 54 (74.0) | |
| ≥1% | 33 (22.1) | 14 (18.4) | 19 (26.0) | |
| N/A | 40 | 17 | 23 | |
| PD-L1 TPS expression | 1.00 | |||
| <1% | 133 (89.3) | 68 (89.5) | 65 (89.0) | |
| ≥1% | 16 (10.7) | 8 (10.5) | 8 (11.0) | |
| N/A | 40 | 17 | 23 | |
| BRCA 1/2 | < 0.001 | |||
| Mutant | 40 (21.2) | 40 (43.0) | 0 (0.00) | |
| Wild-type | 149 (78.8) | 53 (57.0) | 96 (100) | |
| HRR-associated genes | < 0.001 | |||
| Mutant | 68 (36.0) | 49 (52.7) | 19 (19.8) | |
| Wild-type | 121 (64.0) | 44 (47.3) | 77 (80.2) | |
HRD, homologous recombination deficiency. A tumor was defined as HRD+ on the basis of HRD scores ≥ 30 and/or deleterious mutation in BRCA1/2, whereas BRCA1/2-intact tumors with HRD scores < 30 were defined as HRD−. PD-L1, programmed death ligand 1; TPS, tumor proportion score, the proportion of viable tumor cells showing partial or complete membrane PD-L1 staining at any intensity; IPS, immune proportion score (IPS), the percentage of tumor-infiltrating immune cells with PD-L1 staining at any intensity; HRR, homologous recombination repair; N/A, not available.